Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 13;13:7701. doi: 10.1038/s41467-022-35312-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Plasma samples were collected after a BA.2 omicron (n = 12, Panel a) or wild-type infection (n = 10, Panel b) in previously naïve patients (no vaccination and no known history of prior infection) or in patients with hybrid immunity, Panel c two doses of ChAdOx-S1 (AZ/AZ) followed by delta infection (n = 6) and Panel d two doses of BNT162b2 (BNT/BNT) followed by pre-omicron variant (presumably delta) infection (n = 22). Samples were analyzed for 50 % neutralizing antibody titers (IC₅₀) against D614G (blue), alpha (dark green), alpha + E484K (light green), beta (ocher), gamma (purple), delta (orange), BA.1 (red), BA.2 (violet), and BA.5 (pink) omicron. Shown are individual patient samples as circles connected by lines and mean titers as bars. Numbers above bars indicate proportion of positive samples (titers > 1:16). IC₅₀ titers against BA.2 omicron (Panel e; violet) and BA.5 omicron (Panel f; pink) for different groups of individuals with single exposure (non-vaccinated convalescent: ancestral virus conv. n = 10; alpha conv. n = 10; beta conv. n = 9; delta conv. n = 7; BA.1 conv. n = 18; BA.2 conv. n = 12), two exposures with close variants (two doses of vaccine: ChAdOx-S1/ChAdOx-S1 (AZ/AZ) n = 10; ChAdOx-S1/BNT162b2 (AZ/BNT) n = 10; BNT162b2/BNT162b2 (BNT/BNT) n = 11; mRNA-1273/mRNA-1273 n = 10) two exposures with distant variants (re-infection with BA.1 (n = 15) or BA.2 omicron (n = 3) after historic non-omicron infection in unvaccinated), three or more exposures with close variants (three doses of vaccination (BNT162b2/BNT162b2/BNT162b2 (BNT/BNT/BNT) n = 7) or breakthrough infection with delta variant after vaccination (AZ/AZ + delta n = 6; BNT/BNT + delta n = 22)), and three or more exposures with distant variants (breakthrough infection or reinfection with a omicron variant after vaccination (Vacc + BA.1 n = 14; Vacc+BA.2 n = 7; Vacc+BA.1 reinfected n = 11)) were determined. D614G, alpha, beta, gamma, delta, and BA.1 omicron IC₅₀ for these groups have been published previously in^1,2. Shown are individual patients (circles) and geometric mean (bars) for each group. The dotted lines in panels a–f indicate the limit of detection.